Pune, India -- (SBWIRE) -- 10/25/2018 -- This study researches the market size of Recombinant Therapeutic Antibodies and Proteins in United States, European Union and China, presents the Recombinant Therapeutic Antibodies and Proteins sales, revenue, market share and growth rate by companies, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

Free PDF Sample for New Advancements with Applications : https://www.qyresearch.com/sample-form/form/836376/global-united-states-european-union-and-china-recombinant-therapeutic-antibodies-and-proteins-market

The global recombinant therapeutic antibodies and proteins market size was valued at US$ 92.5 billion in 2017, and is expected to witness a robust CAGR of 11.2% over the forecast period (2017 – 2025).

In 2018, the market size of Recombinant Therapeutic Antibodies and Proteins is xx million US$ and it will reach xx million US in 2025, growing at a CAGR of xx% from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US in 2025, with a CAGR of xx% during forecast period.

In this report, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Recombinant Therapeutic Antibodies and Proteins.

In United States, European Union and China market, the following companies are covered:

Abbott

Amgen

Biogen

Eli Lilly

Roche

Johnson and Johnson

Merck

Novo Nordisk

Pfizer

Sanofi

Get more Information about this Report: https://www.qyresearch.com/index/detail/836376/global-united-states-european-union-and-china-recombinant-therapeutic-antibodies-and-proteins-market

Market Segment by Product Type

Plasma Protein

Fusion Proteins

Monoclonal Antibodies

Hormones

Enzyme

Coagulation Factors

Others

Market Segment by Application

Oncology

Hematology

Immunology

Endocrinology

Infectious Disease

Cardiovascular Disease

Others

Key Regions split in this report:

United States

China

European Union

Rest of World (Japan, Korea, India and Southeast Asia)

Industry Insights with Latest And Upcoming Trends : https://www.qyresearch.com/sample-form/form/836376/global-united-states-european-union-and-china-recombinant-therapeutic-antibodies-and-proteins-market

The study objectives are:

To analyze and research the Recombinant Therapeutic Antibodies and Proteins status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the key Recombinant Therapeutic Antibodies and Proteins manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market